543 Bryant Street
81 articles with ProQR Therapeutics
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will present during a fireside chat at the upcoming JMP Securities Life Sciences Conference.
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
10/9/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
4/2/2020Biopharma companies from across the globe provide updates on their pipelines and business practices.
12/16/2019It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
12/12/2019Companies from across the globe provide updates to their business and pipelines.
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced that it received Orphan Drug designation from the Food and Drug Administration for QR-1123.
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced that Company management will present at upcoming investor conferences
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
ProQR Therapeutics N.V. announced the pricing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share.
10/14/2019It was a busy week for clinical trial announcements. Here’s a look.
ProQR Therapeutics N.V. announced positive top-line results from the PQ-110-001 study, a Phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene.
12/17/2018With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
Dinko Valerio offers wisdom garnered from a long career as a scientist, investor and entrepreneur.
Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber's Congenital Amaurosis Type 10
ProQR Therapeutics announced positive interim results from the Phase 1/2 Clinical Trial of QR-110, a trial managed by Ora and featuring Ora's VNC™ mobility courses
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th
Initiated WINGS, the first clinical trial to evaluate the safety and efficacy of QR-313 in patients that have recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene.
Foundation Fighting Blindness Will Provide Up to $7.5M in Funding to Develop Proqr’s Candidate QR-421a for Usher Syndrome Type 2A
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene.